Supernus Announces Paragraph IV ANDA Filings for Qelbree®

Core Insights - Supernus Pharmaceuticals, Inc. has received Paragraph IV Notice Letters from third parties regarding Abbreviated New Drug Applications (ANDAs) for viloxazine extended-release capsules in 100, 150, and 200 mg doses [1][2] - The company is reviewing these Notice Letters and plans to enforce its intellectual property rights related to its product Qelbree, which is protected by six U.S. patents with expiration dates ranging from September 2029 to April 2035 [2] Company Overview - Supernus Pharmaceuticals focuses on developing and commercializing products for central nervous system (CNS) diseases [3] - The company's neuroscience portfolio includes treatments for ADHD, dyskinesia in Parkinson's disease, epilepsy, migraine, and other CNS disorders, with ongoing development of new candidates for epilepsy and depression [4]